Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
13/11/2025 19:01
Nov 13 (Reuters) - Novo Nordisk NOVOb.CO and Eli Lilly LLY.N do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc MGRX.O, spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers. Spokespeople for both companies said in emails to Reuters that they had no special arrangements with the company. Mangoceuticals did not respond to request for comment. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shilpi Majumdar) ((mrinalika.roy@thomsonreuters.com;))
Recent news on Mangoceuticals
See all newsBrief: Mangoceuticals And Nuclea Energy Terminate Business Combination Agreement On August 19
Brief: Mangoceuticals Inc.’S Merger Partner, Nuclea Energy, Inc., Enters Into Definitive Agreement To Acquire Moltex Energy’S Advanced Nuclear Technology Assets
NASDAQ RESUMED AT 10:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM
NASDAQ RESUMED AT 10:27 AM